ქალბატონო ეკატერინე
მოგახსენებთ, რომ დღეს კოვაქსის/გავის მხრიდან მიღებული კომუნიკაციის თანახმად გვიწევს რამდენიმე პროცედურული საკითხის განხორციელება. მათ შორის კოვაქსთან შეთანხმების ცვლილება, რათა იქ აისახოს ჯანმოს გადაუდებელი ავტორიზაციის სტატუსის მქონე ვაქცინები (ნაცვლად სრული ავტორიზაციისა).
ასევე მნიშვნელოავნია სამინისტროს ადმინისტრაციამ გამოყოს ვაქცინის შესყიდვის პროცედურების წარმოებაზე პასუხისმგებელი პირი, რომელიც საგარაო საქმეთა სამმართველოსთან ერთად გააგრძელებს შესაბამის კომუნიკაციას მომწოდებლებთან და საჭიროების შემთხვევაში უცხო ქვეყნის დიპლომატიურ წარმომადგენლებთან.
ნათია ხმალაძეს ვთხოვ დაუყოვნებლიც განიხილოს შემოთავაზებული ცვლილებების ინიცირების საკითხი.
გთხოვთ თქვენს გადაწყვეტილებას ადმინისტრაციიდან ვაქცინის შესყიდვებზე პასუხისმგებელი პირის ნომინირების თაობაზე.
პატივისცემით,
თამარ გაბუნია
მინისტრის პირველი მოადგილე
Sincerely,
Tamar Gabunia, MD, MPH
First Deputy Minister
From: Rosie Grieves (Consultant) [mailto:rgrieves@gavi.org]
Sent: 8 February, 2021 23:49
To: Tamar Gabunia
Cc: Maia Nikoleishvili
Subject: Indicative Allocation Follow-Up
Dear Tamar,
I am still waiting for some information from Pfizer about next steps for the first allocation. I will send this to you as soon as I receive it. In the meantime, I am sending you some documents and information to enable you to move forward with obtaining your AZ doses.
Procurement channel
Please find attached a Procurement and Delivery Q&A document that should guide the next steps in terms of procurement. If you are interested in procuring devices, especially syringes through UNICEF, kindly reach out directly using the contact details in the Q&A Document.
Could you kindly tell me if you are going to use Unicef or if you will self-procure?
Amendment to the Commitment Agreement
As you will appreciate, most of the vaccine supply currently available has received emergency use authorisation and has not yet received standard authorisation. Rather than seeking a waiver each time supply is offered to a participant, we are proposing an amendment to your Commitment Agreement to clarify the status of emergency use authorisations. This amendment allows us to move forward with allocating vaccines that have received emergency use authorisation so as not to hold up timely access to vaccines that we understand participants are keen to receive as soon as possible. The amendment does not preclude the possibility that the vaccine will have achieved standard use authorisation by the time of delivery.
Attached you will find an Amendment to the Commitment Agreement which clarifies the definition of “Approved Vaccine” to include WHO Prequalification, standard/conditional marketing authorisation or an emergency use authorisation in place from an SRA, or a WHO Emergency Use Listing.
In order to facilitate supply of vaccines to participants, we would be grateful if you could return the signed Amendment Letter as soon as possible, and at the latest by close on February 14, 2020.
AstraZeneca Liability and Indemnity
Following the indicative allocation recently shared, your next step should be to contact AstraZeneca directly in order to finalise the Liability and Indemnity terms. These standard Liability and Indemnity terms were shared with you at the opening of Window 2 as part of the information pack and supplemental information pack.
If you have a bilateral deal with AstraZeneca, the Liability and Indemnity the terms of that agreement will supersede the terms shared by the COVAX Facility.
AstraZeneca Point of Contact
Please reach out to Laura Mann at laura.mann@astrazeneca.com to discuss the items above. Thank you for keeping me and covax@gavi.org in copy on all communication with the manufacturer. In anticipation of the volume of enquiries to AstraZeneca, we ask participants to streamline communications through a single point of contact to the extent possible.
Progress on Janssen/Johnson & Johnson negotiations
Following the signing of the MOU with Janssen/Johnson & Johnson in December for 500mn doses of their single-dose vaccine and the release of positive interim efficacy data last week, our negotiations continue to advance. The Facility will look to open Window 1 for Janssen/J&J’s candidate next week. We expect Window 2 to follow around 4-8 weeks after Window 1, subject to successful completion of the Advance Purchase Agreement. We will be in touch with further information about these dates as soon as we can.
Thank you for your continued collaboration with the COVAX Facility. Please do not hesitate to contact me should you have any questions.
Best regards
Rosie Grieves
+44 7849 574189
Office of the COVAX facility
Gavi The Vaccine Alliance
Global Health Campus
Chemin du Pommier 40
1218 Grand-Saconnex
Geneva, Switzerland
Tel: + 41 22 909 65 00
Web: http://www.gavi.org
With the support of donors and partners, Gavi, the Vaccine Alliance is working to immunise an additional 300 million children between 2016 and 2020, preventing a further 5-6 million deaths. Join us and help to reach every child. Visit www.gavi.org, sign up for the Gavi newsletter and follow us on Facebook and Twitter.
NOTICE: This email, including any attachments to it, may be confidential and does not create any binding contract on behalf of Gavi or its partners. If this email was sent to you in error, please notify the sender immediately by reply e-mail, and please do not use, distribute, retain, print or copy the e-mail or any attachment.